Rethinking Diabetes: A Weekly Review
Malattie Metaboliche e Diabetologia
Advances in Diabetes Management and Research
This week we discuss advances in diabetes management including once-weekly insulin combinations, gender differences in hypoglycemia, proteomic risk prediction, and new insights into XLH and adrenal incidentalomas.
Accedi o Registrati per ascoltare questo episodio
Bibliografia
1. Exercise or Fasting in Individuals With Type 2 Diabetes Receiving Once-Weekly Basal Insulin Icodec.
Authors: Pieber TR, Bajaj HS, Fluhr G, et al.
Journal: Diabetes, obesity & metabolism, 2026 Sep
PMID: 42387301
DOI: 10.1111/dom.71050
2. Anthropometric characteristics at birth and growth outcome in patients with X-linked hypophosphatemia treated with oral phosphate and active vitamin D.
Authors: Przygodda S, Brieger LC, Bohlen AV, et al.
Journal: Pediatric nephrology (Berlin, Germany), 2026 Sep
PMID: 41963716
DOI: 10.1007/s00467-026-07271-0
3. A validated, modifiable proteomic score from the EXSCEL trial predicts cardiovascular events in diabetes.
Authors: Corey KM, Nguyen M, Mi MY, et al.
Journal: JCI insight, 2026 Aug 24
PMID: 42390946
DOI: 10.1172/jci.insight.204463
4. Efficacy and Safety of Intensifying Once-Weekly Insulin Icodec Treatment With Once-Weekly Semaglutide in Adults With Type 2 Diabetes: A Single-Arm, Open-Label, Treat-to-Target, Phase 3b Trial (ONWARDS 8).
Authors: Strojek K, Liebl A, Mumbaikar NN, et al.
Journal: Diabetes, obesity & metabolism, 2026 Sep
PMID: 42387310
DOI: 10.1111/dom.71049
5. Temporal changes in cortisol secretion and their association with long-term outcomes in benign adrenal incidentalomas: a retrospective cohort study.
Authors: Suntornlohanakul O, Reimondo G, Ghislieri M, et al.
Journal: The lancet. Diabetes & endocrinology, 2026 Sep
PMID: 42413529
DOI: 10.1016/S2213-8587(26)00098-7
6. Gender differences in hypoglycaemia in type 1 and insulin-treated type 2 diabetes: the Hypo-METRICS study.
Authors: McCarthy A, Kent G, Thomas J, et al.
Journal: Diabetologia, 2026 Sep
PMID: 42322375
DOI: 10.1007/s00125-026-06775-6
7. Steatotic liver disease trajectory: A holistic EASL guidance on the multidisciplinary approach to screening and patient management.
Authors: Brouwer WP, Vonghia L, Thiele M, et al.
Journal: JHEP reports : innovation in hepatology, 2026 Sep
PMID: 42617506
DOI: 10.1016/j.jhepr.2026.101798
8. Sodium zirconium cyclosilicate compared with potassium restriction for hyperkalemia management in type 2 diabetes: The SILVERSTAR trial.
Authors: Hamaguchi M, Hironaka J, Okada H, et al.
Journal: Journal of diabetes investigation, 2026 Sep
PMID: 42423524
DOI: 10.1111/jdi.70388
9. Islet ultrastructure: past achievements and future directions.
Authors: Müller A, Aurrecoechea Duran S, Santos PI, et al.
Journal: Diabetologia, 2026 Sep
PMID: 42426419
DOI: 10.1007/s00125-026-06782-7
10. Oral polychemotherapy to induce remission in newly diagnosed type 2 diabetes: results from a randomized controlled trial.
Authors: Dei Cas A, Aldigeri R, Maglietta G, et al.
Journal: Journal of endocrinological investigation, 2026 Sep
PMID: 42507315
DOI: 10.1007/s40618-026-02930-3
Authors: Pieber TR, Bajaj HS, Fluhr G, et al.
Journal: Diabetes, obesity & metabolism, 2026 Sep
PMID: 42387301
DOI: 10.1111/dom.71050
2. Anthropometric characteristics at birth and growth outcome in patients with X-linked hypophosphatemia treated with oral phosphate and active vitamin D.
Authors: Przygodda S, Brieger LC, Bohlen AV, et al.
Journal: Pediatric nephrology (Berlin, Germany), 2026 Sep
PMID: 41963716
DOI: 10.1007/s00467-026-07271-0
3. A validated, modifiable proteomic score from the EXSCEL trial predicts cardiovascular events in diabetes.
Authors: Corey KM, Nguyen M, Mi MY, et al.
Journal: JCI insight, 2026 Aug 24
PMID: 42390946
DOI: 10.1172/jci.insight.204463
4. Efficacy and Safety of Intensifying Once-Weekly Insulin Icodec Treatment With Once-Weekly Semaglutide in Adults With Type 2 Diabetes: A Single-Arm, Open-Label, Treat-to-Target, Phase 3b Trial (ONWARDS 8).
Authors: Strojek K, Liebl A, Mumbaikar NN, et al.
Journal: Diabetes, obesity & metabolism, 2026 Sep
PMID: 42387310
DOI: 10.1111/dom.71049
5. Temporal changes in cortisol secretion and their association with long-term outcomes in benign adrenal incidentalomas: a retrospective cohort study.
Authors: Suntornlohanakul O, Reimondo G, Ghislieri M, et al.
Journal: The lancet. Diabetes & endocrinology, 2026 Sep
PMID: 42413529
DOI: 10.1016/S2213-8587(26)00098-7
6. Gender differences in hypoglycaemia in type 1 and insulin-treated type 2 diabetes: the Hypo-METRICS study.
Authors: McCarthy A, Kent G, Thomas J, et al.
Journal: Diabetologia, 2026 Sep
PMID: 42322375
DOI: 10.1007/s00125-026-06775-6
7. Steatotic liver disease trajectory: A holistic EASL guidance on the multidisciplinary approach to screening and patient management.
Authors: Brouwer WP, Vonghia L, Thiele M, et al.
Journal: JHEP reports : innovation in hepatology, 2026 Sep
PMID: 42617506
DOI: 10.1016/j.jhepr.2026.101798
8. Sodium zirconium cyclosilicate compared with potassium restriction for hyperkalemia management in type 2 diabetes: The SILVERSTAR trial.
Authors: Hamaguchi M, Hironaka J, Okada H, et al.
Journal: Journal of diabetes investigation, 2026 Sep
PMID: 42423524
DOI: 10.1111/jdi.70388
9. Islet ultrastructure: past achievements and future directions.
Authors: Müller A, Aurrecoechea Duran S, Santos PI, et al.
Journal: Diabetologia, 2026 Sep
PMID: 42426419
DOI: 10.1007/s00125-026-06782-7
10. Oral polychemotherapy to induce remission in newly diagnosed type 2 diabetes: results from a randomized controlled trial.
Authors: Dei Cas A, Aldigeri R, Maglietta G, et al.
Journal: Journal of endocrinological investigation, 2026 Sep
PMID: 42507315
DOI: 10.1007/s40618-026-02930-3
